Therini Bio reveals promising Phase 1a trial results for THN391, a potential breakthrough treatment for neurodegenerative ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of ...

Company is advancing a new class of immunomodulators for autoimmune and inflammatory disorders with high unmet medical need- - ABO21009's ...

Mepolizumab is a humanized monoclonal antibody that specifically binds to interleukin-5, which leads to a reduction in eosinophil counts in blood and tissues. 15-17 Two phase 3 trials, METREX ...

Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company focused on the treatment of immune ...

At the recent SEC meeting for Ophthalmology held on 19th March 2025, the expert panel reviewed the proposal to conduct a ...

A record entirely from the South, in a sector that has always been a thorn in the side. At the University Hospital of Palermo ...